FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378952302> ?p ?o ?g. }

• W4378952302 abstract "Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18F]AlF-OC PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18F]AlF-OC (incremental lesions).Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient.In total, 195 unique lesions were detected: 167 with [68Ga]Ga-DOTATATE and 193 with [18F]AlF-OC. The DR for [18F]AlF-OC was 99.1% versus 91.4% for [68Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18F]AlF-OC, of which 91% were confirmed by MRI and considered true positives.The DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta.gov/study/NCT04552847." @default.
• W4378952302 created "2023-06-02" @default.
• W4378952302 creator A5001010553 @default.
• W4378952302 creator A5001037498 @default.
• W4378952302 creator A5020227571 @default.
• W4378952302 creator A5039079234 @default.
• W4378952302 creator A5040841004 @default.
• W4378952302 creator A5046500019 @default.
• W4378952302 creator A5046922078 @default.
• W4378952302 creator A5050774304 @default.
• W4378952302 creator A5054390362 @default.
• W4378952302 creator A5057457186 @default.
• W4378952302 creator A5059566426 @default.
• W4378952302 creator A5063205694 @default.
• W4378952302 creator A5066111936 @default.
• W4378952302 creator A5067985724 @default.
• W4378952302 creator A5068294771 @default.
• W4378952302 creator A5070524913 @default.
• W4378952302 creator A5072600244 @default.
• W4378952302 creator A5088079795 @default.
• W4378952302 creator A5090645179 @default.
• W4378952302 date "2023-06-01" @default.
• W4378952302 modified "2023-10-18" @default.
• W4378952302 title "Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients" @default.
• W4378952302 cites W1965582434 @default.
• W4378952302 cites W1970515848 @default.
• W4378952302 cites W1988248399 @default.
• W4378952302 cites W2083853142 @default.
• W4378952302 cites W2108525408 @default.
• W4378952302 cites W2149644390 @default.
• W4378952302 cites W2419206450 @default.
• W4378952302 cites W2463848034 @default.
• W4378952302 cites W2508639256 @default.
• W4378952302 cites W2523233937 @default.
• W4378952302 cites W2548317121 @default.
• W4378952302 cites W2594215236 @default.
• W4378952302 cites W2596205188 @default.
• W4378952302 cites W2608160487 @default.
• W4378952302 cites W2619499717 @default.
• W4378952302 cites W2761539086 @default.
• W4378952302 cites W2818233708 @default.
• W4378952302 cites W2968041467 @default.
• W4378952302 cites W2998531620 @default.
• W4378952302 cites W3009086926 @default.
• W4378952302 cites W3034114378 @default.
• W4378952302 cites W3040371898 @default.
• W4378952302 cites W3108181849 @default.
• W4378952302 cites W3162625088 @default.
• W4378952302 cites W3169997136 @default.
• W4378952302 cites W3214005043 @default.
• W4378952302 cites W4200458703 @default.
• W4378952302 cites W4210299335 @default.
• W4378952302 cites W4223931047 @default.
• W4378952302 cites W4306901874 @default.
• W4378952302 cites W4318817556 @default.
• W4378952302 doi "https://doi.org/10.1186/s13550-023-01003-3" @default.
• W4378952302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37261615" @default.
• W4378952302 hasPublicationYear "2023" @default.
• W4378952302 type Work @default.
• W4378952302 citedByCount "1" @default.
• W4378952302 countsByYear W43789523022023 @default.
• W4378952302 crossrefType "journal-article" @default.
• W4378952302 hasAuthorship W4378952302A5001010553 @default.
• W4378952302 hasAuthorship W4378952302A5001037498 @default.
• W4378952302 hasAuthorship W4378952302A5020227571 @default.
• W4378952302 hasAuthorship W4378952302A5039079234 @default.
• W4378952302 hasAuthorship W4378952302A5040841004 @default.
• W4378952302 hasAuthorship W4378952302A5046500019 @default.
• W4378952302 hasAuthorship W4378952302A5046922078 @default.
• W4378952302 hasAuthorship W4378952302A5050774304 @default.
• W4378952302 hasAuthorship W4378952302A5054390362 @default.
• W4378952302 hasAuthorship W4378952302A5057457186 @default.
• W4378952302 hasAuthorship W4378952302A5059566426 @default.
• W4378952302 hasAuthorship W4378952302A5063205694 @default.
• W4378952302 hasAuthorship W4378952302A5066111936 @default.
• W4378952302 hasAuthorship W4378952302A5067985724 @default.
• W4378952302 hasAuthorship W4378952302A5068294771 @default.
• W4378952302 hasAuthorship W4378952302A5070524913 @default.
• W4378952302 hasAuthorship W4378952302A5072600244 @default.
• W4378952302 hasAuthorship W4378952302A5088079795 @default.
• W4378952302 hasAuthorship W4378952302A5090645179 @default.
• W4378952302 hasBestOaLocation W43789523021 @default.
• W4378952302 hasConcept C126322002 @default.
• W4378952302 hasConcept C126838900 @default.
• W4378952302 hasConcept C127077266 @default.
• W4378952302 hasConcept C142724271 @default.
• W4378952302 hasConcept C143409427 @default.
• W4378952302 hasConcept C188816634 @default.
• W4378952302 hasConcept C2775842073 @default.
• W4378952302 hasConcept C2776297358 @default.
• W4378952302 hasConcept C2779066768 @default.
• W4378952302 hasConcept C2781025020 @default.
• W4378952302 hasConcept C2781156865 @default.
• W4378952302 hasConcept C2989005 @default.
• W4378952302 hasConcept C3017724952 @default.
• W4378952302 hasConcept C40993552 @default.
• W4378952302 hasConcept C71924100 @default.
• W4378952302 hasConceptScore W4378952302C126322002 @default.
• W4378952302 hasConceptScore W4378952302C126838900 @default.
• W4378952302 hasConceptScore W4378952302C127077266 @default.

• next